 The tetravalent dengue vaccine, CYDT-DV, demonstrated efficacy against all dengue serotypes in two large phase 3 studies. An integrated summary of the immunogenicity of CYDT-DV was conducted, which identified several parameters driving the neutralizing humeral immune response and evolution over time. The study found that CYDT-DV elicits neutralizing antibody responses against all dengue serotypes, with differences by age and endemicity. These responses persist above baseline levels in endemic countries for up to four years post-dose three. This article was authored by Clairvine, Martin Jupuy, Alain Ristian, and others.